醫(yī)療特長：從事消化內科臨床工作近30年，對炎癥性腸病（克羅恩病、潰瘍性結腸炎）、罕見病（遺傳性血管性水腫、IgG4相關性疾病、家族性地中海熱、糖原累積病等）及自身免疫性腸病、乳糜瀉、PD-1相關免疫性腸炎、蛋白丟失性腸病、P-J綜合征（黑斑息肉病）等小腸疑難疾病的診斷治療有較豐富的經驗，擅長小腸鏡、膠囊內鏡及超聲內鏡，主要研究方向為炎癥性腸病、罕見病及小腸疾病。
研究方向：
炎癥性腸病（克羅恩病、潰瘍性結腸炎）、罕見病、小腸疾病、小腸鏡診治技術
主要教育和工作經歷：
1994年畢業(yè)于中山醫(yī)科大學臨床醫(yī)學系，畢業(yè)后一直在中山大學附屬第一醫(yī)院消化內科工作，2005-2006年到香港威爾斯親王醫(yī)院進修，2007年獲中山大學內科學博士學位。
社會兼職：
1.中華醫(yī)學會消化病學分會炎癥性腸病學組心理協(xié)作組委員；2.中華醫(yī)學會消化內鏡學分會膠囊內鏡協(xié)作組委員；3.廣東省醫(yī)學會消化病學分會炎癥性腸病學組副組長；4.廣東省醫(yī)師學會消化內鏡學醫(yī)師分會小腸內鏡專業(yè)組副組長；5.廣東省醫(yī)師協(xié)會消化科醫(yī)師學分會委員；6.中華炎性腸病雜志青年學術組副組長
論著：
1.Zhang SH, Chen BL(共同第一作者),Wang BM,Chen H,Li Y，Cao Q,Chen MH.Effect of induction therapy with Olamkicept vs placebo on clinical response in patient with active ulcerative colitis.JAMA.2023.329(9):1-10
2.Chen BL,Zhong J,LiXL,Pan F,Ding TJ,Zhang Y,Chen H,Liu F,ZhangZY, Zhang L,Rafal Drozda,Oleksandr Oliinyk Aik Han Goh Chen X Sun X; David T Rubin, William J Sandborn,Chen MH; Efficacy and Safety of Ivarmacitinib in Patients With Moderate-to-Severe, Active, Ulcerative Colitis: A Phase II Study, Gastroenterology, 2022
3.Zhuang XJ,Chen BL(共同第一作者), Huang SS,Han J,Zhou GS,Xu S,Chen MH,Zeng ZR,Zhang SH. Hypermethylation of miR-145 promoter-mediated SOX9-CLDN8 pathway regulates intestinal mucosal barrier in Crohn's disease,EBioMedicine, 2022, 76
4.Chen BL,Gao X,Zhong J,Ren JL,Zhu X, Liu ZJ,Wu KC,Jasmina Kalabic,Yu ZQ,Bidan Huang,Nisha Kwatra,Thao Doan,Anne M. Robinson,Chen HM. Efficacy and safety of adalimumab in Chinese patients with moderately to severely active Crohn's disease: results from a randomized trial, Therap Adv Gastroenterol, 2020, 13.
5.Feng T,Chen BL(共同第一作者),Bella Ungar et al. Association of Infliximab Levels With Mucosal Healing Is Time-Dependent in Crohn’s Disease: Higher Drug Exposure Is Required Postinduction Than During Maintenance Treatment. Inflamm Bowel Dis 2019.25 (11):1813-1821
6.Feng T,Chen B(共同第一作者),Li L, Huang S, Ben-Horin S, Qiu Y, Feng R, Li M, Mao R, He Y, Zeng Z, Zhang S , Chen M. Serum Interleukin 9 Levels Predict Disease Severity and the Clinical Efficacy of Infliximab in Patients with Crohn's Disease. Inflamm Bowel Dis, 2017, 23 (10): 1817-1824.
7.Qiu Y,Chen BL(共同第一作者), Mao R, Zhang SH, He Y, Zeng ZR, Ben-Horin S, Chen MH .Systematic Review with Meta-Analysis: Loss of Response and Requirement of anti-TNFalpha Dose Intensification in Crohn's Disease. J Gastroenterol, 2017, 52 (5): 535-554.
專著：
克羅恩病--基礎研究與臨床實踐
潰瘍性結腸炎--基礎研究與臨床實踐
其他主要工作成績（比如獲獎情況）：無
